Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

by Seamon, Catherine A , Bar, Katharine J , Tebas, Pablo , Refsland, Eric W , O’Dell, Sijy J , Mascola, John R , Clarridge, Katherine E , Hoxie, James A , Scheinfeld, Benjamin , Tressler, Randall L , Graham, Barney S , Overton, Edgar T , Blazkova, Jana , Kreider, Edward F , Salantes, D. Brenda , Learn, Gerald H , Koup, Richard A , Proschan, Michael A , Capparelli, Edmund V , Fauci, Anthony S , Lynch, Rebecca M , Chun, Tae-Wook , Sneller, Michael C , Madden, Patrick J , Justement, J. Shawn , Shiakolas, Andrea R , Kwan, Richard W , Jarocki, Bernadette , Oden, KaSaundra , Moir, Susan , Harrison, Linda J , Bailer, Robert T , Ledgerwood, Julie E , Petrone, Mary E , Bardsley, Mark , Tustin, Nancy B , Doria-Rose, Nicole A , Messer, Michael

in Acquired immune deficiency syndrome / Adult / Aged / AIDS / Allergies / Antibodies / Antibodies, Monoclonal - adverse effects / Antibodies, Monoclonal - pharmacokinetics / Antibodies, Monoclonal - therapeutic use / Antibodies, Neutralizing - adverse effects / Antibodies, Neutralizing - therapeutic use / Antiretroviral drugs / Antiretroviral therapy / Antiviral activity / Binding sites / CD4 antigen / Clinical trials / Female / Historically Controlled Study / HIV / HIV - genetics / HIV - isolation & purification / HIV Infections - drug therapy / HIV Infections - virology / Human immunodeficiency virus / Humans / Immunization (passive) / Immunoglobulins / Immunotherapy / Infectious diseases / Male / Middle Aged / Phylogeny / Plasma / RNA, Viral - blood / Viral infections / Viral Load / Viremia - prevention & control

2016

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

2016

Confirm

Do you wish to request the book?

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

2016

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

Seamon, Catherine A,

Bar, Katharine J,

Tebas, Pablo,

Refsland, Eric W,

O’Dell, Sijy J,

Mascola, John R,

Clarridge, Katherine E,

Hoxie, James A,

Scheinfeld, Benjamin,

Tressler, Randall L,

Graham, Barney S,

Overton, Edgar T,

Blazkova, Jana,

Kreider, Edward F,

Salantes, D. Brenda,

Learn, Gerald H,

Koup, Richard A,

Proschan, Michael A,

Capparelli, Edmund V,

Fauci, Anthony S,

Lynch, Rebecca M,

Chun, Tae-Wook,

Sneller, Michael C,

Madden, Patrick J,

Justement, J. Shawn,

Shiakolas, Andrea R,

Kwan, Richard W,

Jarocki, Bernadette,

Oden, KaSaundra,

Moir, Susan,

Harrison, Linda J,

Bailer, Robert T,

Ledgerwood, Julie E,

Petrone, Mary E,

Bardsley, Mark,

Tustin, Nancy B,

Doria-Rose, Nicole A,

Messer, Michael

2016

Overview

In these trials, passive administration of VRC01, a broadly neutralizing antibody against human immunodeficiency virus that targets the HIV CD4-binding site, had some anti-HIV effect in 24 persons with chronic HIV infection. Therapeutic administration of monoclonal antibodies has revolutionized treatment options in oncology, rheumatology, endocrinology, gastroenterology, neurology, and the field of infectious diseases. 1 , 2 The use of broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) is a potential approach to the prevention of HIV infection and its therapy and cure. 3 , 4 VRC01 is a bNAb that targets the CD4-binding site of the HIV envelope glycoprotein. VRC01 has been shown to neutralize approximately 90% of a broad panel of 190 group M HIV envelope pseudotyped viruses with a mean 50% inhibitory concentration (IC 50 ) of 0.33 μg per milliliter. 5 Passive administration . . .

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Acquired immune deficiency syndrome

/ Adult

/ Aged

/ AIDS

/ Allergies

/ Antibodies

/ Antibodies, Monoclonal - adverse effects